Merck’s Keytruda flunks pivotal studies in early-stage lung and skin cancers
Fierce Pharma
AUGUST 29, 2024
A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. | A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.
Let's personalize your content